Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) — Capital Reinvestment Ratio
Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has a Capital Reinvestment Ratio of 0.13x as of March 2026, meaning it reinvests 0% of its operating cash flow (TL180.45 Million) in capital expenditures (TL24.08 Million). Check tangible equity quality of Meditera Tibbi Malzeme Sanayi ve Ticaret to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Capital Reinvestment Ratio (2020–2025)
This chart tracks Meditera Tibbi Malzeme Sanayi ve Ticaret AS's Capital Reinvestment Ratio across 6 annual periods. For the full cash flow conversion analysis, see Meditera Tibbi Malzeme Sanayi ve Ticaret operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2020–2025)
Year-by-year Capital Reinvestment Ratio for Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2020 to 2025. See Meditera Tibbi Malzeme Sanayi ve Ticaret free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TRY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.44x | TL435.35 Million | TL191.67 Million | ▲ +30.4% |
| 2024 | 0.34x | TL780.69 Million | TL263.52 Million | ▼ -9.8% |
| 2023 | 0.37x | TL801.02 Million | TL299.70 Million | ▼ -96.3% |
| 2022 | 10.07x | TL5.10 Million | TL51.35 Million | ▲ +4036.4% |
| 2021 | 0.24x | TL36.64 Million | TL8.92 Million | ▼ -14.5% |
| 2020 | 0.28x | TL73.26 Million | TL20.85 Million | — |